HR20013

Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy

Fujian Shengdi Pharmaceutical Co., Ltd.Phase 3Active

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

65 Active assets in the Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy cohort.

Asset / Sponsor	Phase	Rating
DEXAMETHASONE Instituto do Cancer do Estado de São Paulo	Phase 4	A
Palonosetron Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 4	A
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 4	BBB
Netupitant Instituto Brasileiro de Controle do Cancer	Phase 3	BB
Docetaxel The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 4	BB

View all 50 →

Order a full diligence report on this asset.

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.